Skip to content
Boost Up Blog – Lifestyle
Author:
Prelude Therapeutics, Incorporated
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
October 15, 2026
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
September 10, 2026
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 20, 2026
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
April 20, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
April 20, 2026